Trial · NCT01074437
Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)
NCT01074437, Phase 2, Terminated, Seattle Children's Hospital; results first posted 2013-09-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH). Trials, record NCT01074437. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01074437
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)
- NCT number
- NCT01074437
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 9 participants, actual
- Lead sponsor
- Seattle Children's Hospital
- Conditions
- Hemangioma
- Interventions
- Prednisolone (Corticosteroid), Propranolol, Placebo
- First posted
- 2010-02-24
- Last updated
- 2018-10-04
- Results first posted
- 2013-09-26
- Limitations and caveats
- Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Compare Changes in IH Size and Vascularity for the Two Treatment Groups | 1, 2, and 6 months after treatment initiation | This outcome cannot be evaluated. Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable. |
| Primary | Lesion Regression | 12 months | measure of change in lesion area or volume |
| Secondary | Determine Therapeutic Response of IH to Propranolol Among Patients Who Switch to Corticosteroids Plus Propranolol Therapy After Failing to Respond to Corticosteroids Alone. | 1, 2, and 6 months after treatment initiation | This outcome cannot be evaluated. Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable. |
| Secondary | Assess the Safety of Propranolol With Corticosteroids and Corticosteroids Alone in the Treatment of IH. | 1, 2 and 6 months after treatment initiation | This outcome cannot be evaluated. Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable. |
| Secondary | Demonstrate How Duplex Scanning to Assess Blood Vessel Density and Qualitative Color Ratings of Cutaneous Lesions From Photographs Can be Used to Measure and Quantify Changes in IH Size and Vascularity in a Clinically Relevant Manner. | 1, 2 and 6 months after treatment initiation | This outcome cannot be evaluated. Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Compare Changes in IH Size and Vascularity for the Two Treatment Groups | 1, 2, and 6 months after treatment initiation | This outcome cannot be evaluated. Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable. | ||
| PRIMARY | Lesion Regression | 12 months | Insufficient enrollment for data analysis to be meaningful. | ||
| SECONDARY | Determine Therapeutic Response of IH to Propranolol Among Patients Who Switch to Corticosteroids Plus Propranolol Therapy After Failing to Respond to Corticosteroids Alone. | 1, 2, and 6 months after treatment initiation | This outcome cannot be evaluated. Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable. | ||
| SECONDARY | Assess the Safety of Propranolol With Corticosteroids and Corticosteroids Alone in the Treatment of IH. | 1, 2 and 6 months after treatment initiation | This outcome cannot be evaluated. Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable. | ||
| SECONDARY | Demonstrate How Duplex Scanning to Assess Blood Vessel Density and Qualitative Color Ratings of Cutaneous Lesions From Photographs Can be Used to Measure and Quantify Changes in IH Size and Vascularity in a Clinically Relevant Manner. | 1, 2 and 6 months after treatment initiation | This outcome cannot be evaluated. Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A: Corticosteroid With Placebo | 4 | |
| Overall Study | STARTED | Group B: Corticosteroid With Propranolol | 5 | |
| Overall Study | COMPLETED | Group A: Corticosteroid With Placebo | 4 | |
| Overall Study | COMPLETED | Group B: Corticosteroid With Propranolol | 5 | |
| Overall Study | NOT COMPLETED | Group A: Corticosteroid With Placebo | 0 | |
| Overall Study | NOT COMPLETED | Group B: Corticosteroid With Propranolol | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A: Corticosteroid With Placebo | ||
| Total, all-cause mortality | Group B: Corticosteroid With Propranolol | ||
| Total, other adverse events | Group A: Corticosteroid With Placebo | 0 | 4 |
| Total, other adverse events | Group B: Corticosteroid With Propranolol | 0 | 5 |
| Total, serious adverse events | Group A: Corticosteroid With Placebo | 0 | 4 |
| Total, serious adverse events | Group B: Corticosteroid With Propranolol | 0 | 5 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Group A: Corticosteroid With Placebo vs Group B: Corticosteroid With Propranolol: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01074437
GET https://conductscience.org/api/trials/v1/NCT01074437/registered